Literature DB >> 3924464

Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults.

L A Bauer, R Davis, A Wilensky, V Raisys, R H Levy.   

Abstract

Six young (22 to 25 years old) and six elderly (60 to 88 years old) healthy adults took valproic acid, 250 mg by mouth, at 8 am and 8 pm for 5 days. On the fifth day, blood samples were drawn over each dosage interval. Both young and elderly subjects exhibited diurnal variability. Total and unbound clearances in the young and elderly subjects were about 10% and 15% higher during the evening. These changes led to lower total and unbound steady-state and peak concentrations during the nighttime dosage interval. There were no differences in total steady-state concentrations and kinetics computed from total concentrations between the young and elderly, but there were differences in unbound steady-state concentrations and kinetics. Unbound clearances were 65% lower, which resulted in unbound steady-state concentrations 67% higher in the elderly. The average unbound fractions in the elderly and young were 10.7% and 6.4%. To minimize the influence of diurnal variability, drug concentrations should be determined at the same time each day. Total valproic acid concentration data may be less useful in elderly patients; unbound concentrations may be more reliable in this population.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924464     DOI: 10.1038/clpt.1985.116

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  20 in total

Review 1.  Age-related changes in protein binding of drugs: implications for therapy.

Authors:  M K Grandison; F D Boudinot
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

Review 2.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

3.  The 'apparent clearance' of free phenytoin in elderly vs. younger adults.

Authors:  Daniel F B Wright; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 4.  Nonlinear pharmacokinetics: clinical Implications.

Authors:  T M Ludden
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

5.  Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.

Authors:  R L Smith; T Haslemo; H Refsum; E Molden
Journal:  Eur J Clin Pharmacol       Date:  2016-06-29       Impact factor: 2.953

Review 6.  Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 7.  Plasma protein binding of drugs in the elderly.

Authors:  S M Wallace; R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

8.  A systematic review of population pharmacokinetics of valproic acid.

Authors:  Janthima Methaneethorn
Journal:  Br J Clin Pharmacol       Date:  2018-02-28       Impact factor: 4.335

Review 9.  Drug treatment of epilepsy in elderly people: focus on valproic Acid.

Authors:  Linda J Stephen
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Pharmacokinetic optimisation of drug therapy in elderly patients.

Authors:  B M Parker; B J Cusack; R E Vestal
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.